Synergistic antitumor activity of cyclophosphamide and ABPP in the treatment of established and advanced tumors in murine tumor models
- 1 July 1987
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 25 (1) , 16-24
- https://doi.org/10.1007/bf00199296
Abstract
We have previously shown that the in vivo administration of ABPP, an interferon inducing pyrimidinone, generates activated killer cells that can lyse fresh tumor cells in vitro in 4-h 51chromium release assays. The administration of this agent however has no effect on established tumor. In this communication we show that ABPP, when used in combination with low or moderate doses of cyclophosphamide, can be quite effective against early established (day 3) tumor as well as against advanced, grossly visible (day 8–10) tumor in both the i.p. and pulmonary metastasis model. The synergistic antitumor activity of this cheoimmunotherapeutic regimen was very strong against immunogenic tumors but rather weak against nonimmunogenic tumors. Two treatment cycles were significantly more effective than one and multiple cycles even cured the majority of mice with established i.p. tumor. These experiments demonstrate the potential of chemoimmunotherapeutic regimens and highlight the efficacy of multiple treatment cycles.Keywords
This publication has 28 references indexed in Scilit:
- In vivo generation of lymphokine activated killer cell activity by ABPP and interleukin-2 and their antitumor effects against immunogenic and nonimmunogenic tumors in murine tumor modelsCancer Immunology, Immunotherapy, 1988
- INHIBITORY EFFECTS OF ALLOIMMUNE T-CELLS ON THE GENERATION OF CYTOLYTIC RESPONSES OF LYMPHOKINE-ACTIVATED KILLER-CELLS1987
- Alloimmune cells consume interleukin-2 and competitively inhibit the anti-tumour effects of interleukin-2British Journal of Cancer, 1987
- The structural and functional assessment of cytotoxic injury of the immune system with particular reference to the effects of ionizing radiation and cyclophosphamide.1986
- Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells.The Journal of Experimental Medicine, 1985
- Mechanism of antitumor action of pyrimidinones in the treatment of B16 melanoma and P388 leukemia.1985
- LYMPHOKINE-ACTIVATED KILLER CELLS - LYSIS OF FRESH SYNGENEIC NATURAL KILLER-RESISTANT MURINE TUMOR-CELLS BY LYMPHOCYTES CULTURED IN INTERLEUKIN-21984
- 5-halo-6-phenyl pyrimidinones: new molecules with cancer therapeutic potential and interferon-inducing capacity are strong inducers of murine natural killer cells.The Journal of Immunology, 1983
- Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.The Journal of Experimental Medicine, 1982
- A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES.1965